Novartis Ag (NVS) Depreciation & Amortization (CF) (2009 - 2018)

Novartis Ag has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $930.0 million in Q1 2018.

• Quarterly Depreciation & Amortization (CF) changed N/A year-over-year to $930.0 million in Q1 2018, while the trailing twelve-month figure through Dec 2018 was $930.0 million (down 85.31% YoY) and the FY2009 annual result came in at $2341.0, changed N/A from the prior year.
• Depreciation & Amortization (CF) fell to $930.0 million in Q1 2018 per NVS's latest filing, from $6.3 billion in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $6.3 billion in Q4 2017 and troughed at $930.0 million in Q1 2018.
• A 5-year average of $4.8 billion and a median of $5.6 billion in 2015 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2015 and 2017: Depreciation & Amortization (CF) grew 17.34% in 2015, then advanced 2.54% in 2017.
• Over 5 years, Depreciation & Amortization (CF) stood at $4.8 billion in 2014, then grew by 17.34% to $5.6 billion in 2015, then grew by 10.76% to $6.2 billion in 2016, then climbed by 2.54% to $6.3 billion in 2017, then plunged by 85.31% to $930.0 million in 2018.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $930.0 million, $6.3 billion, and $6.2 billion for Q1 2018, Q4 2017, and Q4 2016 respectively.